CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 144 Insider Sale of Securities
- 4 Open-market sale 10% owner sold 220,714 shares at an average $33.68 ($7,433,459)
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-3ASR Offering Registration Statement
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale 10% owner sold 50,000 shares at $33.75 ($1,687,500)
- 4 Open-market sale Chief Legal Officer sold 3,586 shares at $34.49 ($123,672)
- 4 Open-market sale 10% owner sold 50,000 shares at an average $34.73 ($1,736,352)
- 4 Open-market sale 10% owner sold 100,000 shares at an average $35.78 ($3,578,103)
- 5 Insider Annual Insider Trading Report
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Regulation FD disclosure
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Chief Medical Officer sold 2,034 shares at an average $36.30 ($73,831)
- 4 Open-market sale Co-Chief Executive Officer sold 5,968 shares at an average $36.30 ($216,629)
- 4 Open-market sale Chief Financial Officer sold 2,658 shares at an average $36.30 ($96,481)
Page 17 of 23 · 446 filings